Keenova Therapeutics plc
CIK: 0001567892
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filer
State of Incorporation Ireland
Country Ireland
Business Address COLLEGE BUSINESS & TECHNOLOGY PARK, DUBLIN 15, , D15
Mailing Address COLLEGE BUSINESS & TECHNOLOGY PARK, DUBLIN 15, , D15
Phone 353 1 6960000
Fiscal Year End 1231
EIN 981088325
Financial Overview
FY2024
$477.90M
Net Income
$382.60M
Cash & Equivalents
$-3.69
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 13, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 11, 2026 | View on SEC |
| 4 Insider stock transaction report | January 9, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
Insider Trading
STRONG BUY 1 insiders
4 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.